3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Burkitt Lymphoma
5
Prostatic Neoplasms
4
Neoplasms
4
Leukemia, Biphenotypic, Acute
4
Ovarian Neoplasms
3
Lymphoma, Follicular
3
Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Metastatic Castration-resistant Prostate Cancer
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Hodgkin Disease
2
Endometrial Neoplasms
2
Down Syndrome
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Myasthenia Gravis
1
Lymphoma, T-Cell, Peripheral
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Adrenal Insufficiency
1
Interventions
Cyclophosphamide
25
fludarabine
19
Dexamethasone
17
pembrolizumab
13
Rituximab
12
venetoclax
9
Lenalidomide
9
Gemcitabine
9
Etoposide
9
pomalidomide
8
Vincristine
7
glofitamab
6
fludarabine phosphate
6
carfilzomib
6
Temozolomide
6
obinutuzumab
5
daratumumab
5
Prednisone
5
Nivolumab
5
Doxorubicin
5
Cisplatin
5
Calcium Dobesilate
5
Bortezomib
5
zanubrutinib
4
selinexor
4
Immunotherapy, Adoptive
4
Cytarabine
4
Carboplatin
4
Azacitidine
4
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Prednisolone
×
90 days
×
Clear all
NCT05888493
2026-04-17
LEDA
Novartis
Phase 3
Active not recruiting
109 enrolled